Having trouble accessing articles? Reset your cache.

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

Ono gets local rights to Forty Seven's mAb
Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights in certain Asian territories to 5F9, a humanized mAb targeting CD47, as monotherapy or in combinations for all indications. The deal covers Japan, South Korea,

Read the full 442 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE